Avanos Medical (AVNS) Finished Goods (2014 - 2026)

Avanos Medical (AVNS) has 13 years of Finished Goods data on file, last reported at $78.2 million in Q1 2026.

• For the quarter ending Q1 2026, Finished Goods rose 4.55% year-over-year to $78.2 million; the trailing twelve-month figure through Mar 2026 stood at $78.2 million (up 4.55% YoY), and the FY2025 full-year result was $84.0 million, up 7.28% from the prior year.
• Finished Goods retreated to $78.2 million in Q1 2026, from $84.0 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $103.4 million in Q1 2023 to a low of $69.8 million in Q4 2022.
• A 5-year average of $83.4 million and a median of $84.0 million in 2024 frame the typical range for Finished Goods.
• Across the five-year window, Finished Goods gained 29.57% in 2023 and dropped 18.76% in 2024, its largest moves.
• Tracing AVNS's Finished Goods over 5 years: stood at $69.8 million in 2022, then gained by 26.79% to $88.5 million in 2023, then retreated by 11.53% to $78.3 million in 2024, then advanced by 7.28% to $84.0 million in 2025, then retreated by 6.9% to $78.2 million in 2026.
• Business Quant data shows AVNS's Finished Goods at $78.2 million in Q1 2026, $84.0 million in Q4 2025, and $80.2 million in Q3 2025.